Objective
"At least 20% of human malignancies are caused by consequences of persistent infections. High-risk human papillomavirus (HPV) types cause over 500.000 cancer cases per year, rendering HPV the #2 human carcinogen after tobacco. Infection-related tumors are attractive targets for cancer vaccination, as they provide the opportunity to target antigens that are immunological non-self. Vaccination can be prophylactic, inducing immune responses preventing infection in the first place, or therapeutic, stimulating the immune system into eradicating established disease. Prophylactic immunization against HPV has become the paradigm for cancer immunoprevention. Unfortunately, current HPV vaccines have no therapeutic effect on existing infections.
Studies on spontaneously regressing HPV-induced lesions show that cell-mediated immune responses are crucial in clearing established HPV infection. Cytotoxic T cells (CTL) kill infected cells after recognizing viral epitopes presented on HLA molecules on the cell surface. There are hundreds of different HLA types, and a given epitope is only applicable for the fraction of patients with the relevant HLA molecule.
This project will define a set of T cell epitopes that elicit CTL-mediated HPV protection in the entire population, by including epitopes for all HLA supertypes. The applicant has established a methodology of determining which viral epitopes are presented on target cells during her past mobility period in the US. HPV-transformed cells of various HLA backgrounds are analyzed by nanospray mass spectrometry. Identified peptides are tested for immunogenicity and the ability to induce CTL. From these tests, a minimal set of functional epitopes providing >95% population protection coverage is selected for vaccine formulation.
The technology is currently transferred to the DKFZ. If this epitope-specific, yet widely applicable therapeutic vaccination approach is successful, it can be used as a platform technology in other malignancies."
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology cervical cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2011-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
69120 Heidelberg
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.